secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-04-19T23:59:59+00:00
Accession:  0000950170-22-005787
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics cuts 20% of workforce (37 FTE); focuses on CDI and ASD after FDA clinical hold
--------------------------------------------------------------------------------

- Reduction of 37 full-time employees (~20% of workforce) approved by board on April 14, 2022.
- Estimates ~$1.1M in one-time severance and related costs, recorded in Q2 2022.
- Restructuring follows FDA clinical hold on CP101 (SARS-CoV-2 donor screening) and pause of chronic hepatitis B program.
- Company has submitted complete response to FDA on clinical hold and awaits feedback.
- Prioritizing recurrent C. difficile infection (CDI) and autism spectrum disorder (ASD) programs; Takeda-partnered IBD work continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/0000950170-22-005787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022005787/fnch-20220414.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer